C0079349||fibroblast growth factor 1
C1254351||conjugate
C0060369||fibroblast growth factor receptor
C3854476||targeted cancer therapy
C0060369||Fibroblast growth factor receptors
C0060369||Fibroblast growth factor receptors
C0920425||cancer therapy
C1514559||overexpressed
C0027651||tumors
C1458155||breast
C0033578||prostate
C0005695||bladder
C0242379||lung cancer
C1749457||natural ligand
C0060369||FGFR
C0034861||engineered variant
C0079349||fibroblast growth factor 1
C0079349||FGF1V
C0522529||conjugated
C0304497||potent cytotoxic drug
C1565020||monomethyl auristatin E
C1565020||monomethyl auristatin E
C0599894||targeting agent
C0334227||cancer cells
C1514559||overexpressing
C0060369||Fibroblast growth factor receptors
C0003241||antibodies
C2346828||antibody-drug conjugates
C1254351||FGF1V-valine-citrulline-MMAE conjugate
C1327386||stability profile
C1167622||bound
C0060369||Fibroblast growth factor receptors
C0699040||cell surface
C1565020||drug (MMAE)
C0597304||cleavage
C0699919||lysosomal protease cathepsin B
C1254351||conjugate
C0596402||cytotoxic effect
C0334227||cell lines
C0060369||FGFR
C1254351||FGF1V-vcMMAE
C1565020||monomethyl auristatin E
C0060369||FGFR
C0334227||cells
C0060369||FGFR
C1513916||did not show
C0007587||mortality